Research programme: second generation factor IX molecules - Catalyst Biosciences

Drug Profile

Research programme: second generation factor IX molecules - Catalyst Biosciences

Alternative Names: CB 2679d; CB 2679d/ISU304; CB FIX; FIX proteases - Catalyst Biosciences; FIX-NG; ISU 304; Recombinant human Factor IX variants - Catalyst Biosciences

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Catalyst Biosciences
  • Developer Catalyst Biosciences; ISU Abxis
  • Class Blood coagulation factors; Peptide hydrolases
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia B

Most Recent Events

  • 28 Mar 2017 Korean Ministry of Food and Drug Safety (MFDS) approves IND application for CB 2679d/ISU304 in Haemophilia B (SC)
  • 14 Nov 2016 Pharmacokinetics data from a preclinical studies in Haemophilia B released by Catalyst Biosciences
  • 04 Aug 2016 Catalyst Biosciences and ISU Abix plan a phase I/II trial for Haemophilia B in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top